Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Pioglitazone

First Posted Date: 2013-12-06

Last Posted Date: 2016-11-10

Lead Sponsor: Takeda

Target Recruit Count: 899

Registration Number: NCT02003014

Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"

Completed

Conditions: Impaired Glucose Tolerance

Interventions: Drug: Voglibose

First Posted Date: 2013-11-25

Last Posted Date: 2018-12-04

Lead Sponsor: Takeda

Target Recruit Count: 742

Registration Number: NCT01993927

Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms

Completed

Conditions: Gastroesophageal Reflux Disease With Dyspepsia Symptoms

Interventions: Drug: Lansoprazole

First Posted Date: 2013-11-21

Last Posted Date: 2016-09-27

Lead Sponsor: Takeda

Target Recruit Count: 14965

Registration Number: NCT01990339

Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin/Pioglitazone

First Posted Date: 2013-11-21

Last Posted Date: 2023-09-18

Lead Sponsor: Takeda

Target Recruit Count: 3281

Registration Number: NCT01990300

Fasiglifam 25 mg BID vs 50 mg QD

Phase 2

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Fasiglifam
Drug: Placebo to fasiglifam

First Posted Date: 2013-11-13

Last Posted Date: 2016-10-07

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT01982253

Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy

Phase 4

Completed

Conditions: Type II Diabetes Mellitus

Interventions: Drug: Pioglitazone
Drug: Metformin
Drug: Sulfonylurea

First Posted Date: 2013-10-30

Last Posted Date: 2018-09-12

Lead Sponsor: Takeda

Target Recruit Count: 114

Registration Number: NCT01972724

Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults

Phase 1

Completed

Conditions: Erectile Dysfunction
Phosphodiesterase 5 Inhibitor

Interventions: Drug: Udenafil
Drug: Placebo

First Posted Date: 2013-10-22

Last Posted Date: 2013-10-22

Lead Sponsor: Takeda

Target Recruit Count: 83

Registration Number: NCT01967264

Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction

Phase 2

Withdrawn

Conditions: Erectile Dysfunction
Benign Prostatic Hyperplasia

Interventions: Drug: Placebo
Drug: Udenafil

First Posted Date: 2013-10-22

Last Posted Date: 2016-03-04

Lead Sponsor: Takeda

Registration Number: NCT01967251

Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides

Completed

Conditions: Surveillance

First Posted Date: 2013-10-17

Last Posted Date: 2017-04-13

Lead Sponsor: Takeda

Target Recruit Count: 1096

Registration Number: NCT01964976

Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin

First Posted Date: 2013-10-17

Last Posted Date: 2019-11-21

Lead Sponsor: Takeda

Target Recruit Count: 19192

Registration Number: NCT01964963

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy